Physician profile
Joey Gamayon Seson
NPI 1932975091
$47,702.00
in general payments reported to CMS, 2019-2025
9 companies · $42K in 2025
The $42K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $375 · 2024: $4,850 · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $6,899 · Consulting Fee: $5,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $22,827.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,375.00 |
| Food and Beverage | $6,899.13 |
| Consulting Fee | $5,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $31,318.76 | 2023-2025 | |
| Revance Therapeutics, INC. | $14,913.67 | 2024-2025 | Daxxify |
| Abbvie INC. | $834.24 | 2023-2025 | |
| Galderma Laboratories, L.P. | $236.02 | 2023-2025 | Dysport |
| Lilly USA, LLC | $125.00 | 2024 | Mounjaro |
| Regeneron Healthcare Solutions, INC. | $124.70 | 2024 | Dupixent |
| Tempus Ai, INC | $89.96 | 2024-2025 | Xt Cdx |
| Organogenesis INC. | $34.68 | 2025 | Apligraf |
| Novo Nordisk INC | $24.97 | 2023 | Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joey Seson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.